- Home
- SBET vs AUPH Comparison
SBET vs AUPH Comparison
Compare SBET & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBET | AUPH |
|---|---|---|
| Founded | 1995 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 1997 | 1999 |
Fundamental Metrics
Financial Performance| Metric | SBET | AUPH |
|---|---|---|
| Price | $6.63 | $14.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $24.80 | $17.25 |
| AVG Volume (30 Days) | ★ 7.7M | 953.2K |
| Earning Date | 03-16-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | $13,106,030.00 | ★ $265,808,000.00 |
| Revenue This Year | $26,752.44 | $21.76 |
| Revenue Next Year | $1.34 | $16.45 |
| P/E Ratio | ★ N/A | $25.92 |
| Revenue Growth | ★ 239.01 | 20.62 |
| 52 Week Low | $2.26 | $6.55 |
| 52 Week High | $124.12 | $16.54 |
Technical Indicators
Market Signals| Indicator | SBET | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 30.12 | 42.16 |
| Support Level | $6.02 | $14.35 |
| Resistance Level | $10.21 | $15.47 |
| Average True Range (ATR) | 0.57 | 0.47 |
| MACD | -0.37 | -0.02 |
| Stochastic Oscillator | 13.97 | 18.70 |
Price Performance
Historical ComparisonAbout SBET SharpLink Gaming Ltd.
SharpLink Gaming Inc is one of the world's largest publicly traded companies to adopt ETH as its primary treasury reserve asset - a move that aligns the Company with the future of digital capital and gives investors direct exposure to Ethereum, the world's smart-contract platform and second largest digital asset.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.